scholarly journals 1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America

2021 ◽  
Vol 32 ◽  
pp. S917
Author(s):  
T. Kolarova ◽  
M. McDonnell ◽  
C.V. Bouvier ◽  
M.E. Pavel ◽  
H. Singh ◽  
...  
Keyword(s):  
North America ◽  
Neuroendocrine Tumor ◽  
Comparative Data ◽  
Tumor Patients ◽  
Medical Oncologists

scholarly journals Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Aman Chauhan ◽  
Satya Das ◽  
Rachel Miller ◽  
Laura Luque ◽  
Samuel N. Cheuvront ◽  
...  
Keyword(s):  
Amino Acid ◽  
Neuroendocrine Tumor ◽  
Gastrointestinal Symptoms ◽  
Retrospective Chart Review ◽  
Final Analysis ◽  
Acid Mixture ◽  
Tumor Patients ◽  
Short Gut Syndrome ◽  
Oral Rehydration ◽  
The Mean

Abstract Background Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. Methods A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. Results Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3–20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0–11). Conclusions Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients.

scholarly journals Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC

2019 ◽  
Vol 61 (7) ◽  
pp. 1014-1020 ◽  
Author(s):  
Elin Pauwels ◽  
Sofie Van Binnebeek ◽  
Vincent Vandecaveye ◽  
Kristof Baete ◽  
Hubert Vanbilloen ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Patients

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

2008 ◽  
Vol 26 (20) ◽  
pp. 3403-3410 ◽  
Author(s):  
Matthew H. Kulke ◽  
Heinz-Josef Lenz ◽  
Neal J. Meropol ◽  
James Posey ◽  
David P. Ryan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Objective Response ◽  
Pancreatic Neuroendocrine Tumor ◽  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Patients ◽  
Patient Reported

Purpose Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line–derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients. Patients and Methods Patients were treated with repeated 6-week cycles of oral sunitinib (50 mg/d for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events. Patient-reported outcomes were assessed. Results Among 109 enrolled patients, 107 received sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66). Overall objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (45 of 66 patients) had stable disease (SD). Among carcinoid patients, ORR was 2.4% (one of 41 patients), and 83% (34 of 41 patients) had SD. Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients. One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients. No significant differences from baseline in patient-reported quality of life or fatigue were observed during treatment. Conclusion Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. Randomized trials of sunitinib in patients with neuroendocrine tumors are warranted.

The antidiarrheal efficacy of a proprietary amino acid mixture (enterade) in neuroendocrine tumor (NET) patients: Updated data.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 614-614
Author(s):  
Aman Chauhan ◽  
Rachel C. Miller ◽  
Laura Luque ◽  
Heidi Weiss ◽  
Lowell Brian Anthony
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumor ◽  
Somatostatin Analogs ◽  
Tumor Resection ◽  
Bacterial Overgrowth ◽  
Unknown Primary ◽  
Acid Mixture ◽  
Tumor Patients ◽  
Short Gut Syndrome

614 Background: Diarrhea is a common quality of life limiting symptom seen in neuroendocrine tumor patient. Diarrhea in these patients could be due to excessive serotonin production, secondary to post-operative short gut syndrome, steatorrhea from somatostatin analogs, bile acid colitis or intestinal bacterial overgrowth. In this study we summarize our single center experience with enterade. Methods: Medical records of all the NET patients treated with enterade for symptomatic diarrhea were retrospectively reviewed after appropriate IRB approval. Patients were treated at Markey cancer center between May 2017-June 2019. Results: Total 98 patients were offered enterade. enterade was instructed to be taken as one 8 Oz bottle BID for 1 week. Antidiarrheal efficacy data was available on 49 patients at the time of abstract submission. 37 (75%) patients had GEPNETs, 8 had bronchial NETs, 1 gynecological NET and 3 patients had unknown primary. 28 (57%) patients had history of prior bowel resection either for primary neuroendocrine tumor resection or debulking. 28 (57%) patients were on somatostatin analog at the time of initiation of enterade. 42 (85%) out of 49 patients reported subjective improvement in diarrheal symptoms. 27 (64%) out of these 42 responders reported at least 50 percent reduction in diarrhea frequency. Conclusions: 85% (42/49) neuroendocrine tumor patients reported improvement in diarrhea with enterade. 64% (27/42) reported more than 50% reduction in diarrhea frequency. A prospective Phase II study of enterade in neuroendocrine tumor patients with quality of life limiting diarrhea is currently being conducted (NCT03722511).

scholarly journals Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Jian-Xian Chen ◽  
Yan Lin ◽  
Yi-Liang Meng ◽  
Ai-Xia Zhao ◽  
Xiao-Juan Huang ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Prothrombin Time ◽  
Survival Probability ◽  
Lymphatic Metastasis ◽  
International Normalized Ratio ◽  
Tumor Differentiation ◽  
Training Set ◽  
Tumor Patients ◽  
Tumor Metastases ◽  
Validation Set

Purpose. The purpose of this study was to develop and initially validate a nomogram model in order to predict the 3-year and 5-year survival rates of neuroendocrine tumor patients. Methods. Accordingly, 348 neuroendocrine tumor patients were enrolled as study objects, of which 244 (70%) patients were included in the training set to establish the nomogram model, while 104 (30%) patients were included in the validation set to verify the robustness of the model. First, the variables related to the survival rate were determined by univariable analysis. In addition, variables that were sufficiently significant were selected for constructing the nomogram model. Furthermore, the concordance index (C-index), receiver operating characteristic (ROC), and calibration curve analysis were used to evaluate the performance of the proposed nomogram model. The survival analysis was then used to evaluate the return to survival probability as well as the indicators of constructing the nomogram model. Results. According to the multivariable analysis, lymphatic metastasis, international normalized ratio (INR), prothrombin time (PT), tumor differentiation, and the number of tumor metastases were found to be independent predictors of survival rate. Moreover, the C-index results demonstrated that the model was robust in both the training set (0.891) and validation set (0.804). In addition, the ROC results further verified the robustness of the model either in the training set ( AUC = 0.823 ) or training set ( AUC = 0.768 ). Furthermore, the calibration curve results showed that the model can be used to predict the 3-year and 5-year survival probability of neuroendocrine tumor patients. Meaningfully, five variables were found: lymphatic metastasis ( p = 0.0095 ), international standardized ratio ( p = 0.024 ), prothrombin time ( p = 0.0036 ), tumor differentiation ( p = 0.0026 ), and the number of tumor metastases ( p = 0.00096 ), which were all significantly related to the 3-year and 5-year survival probability of neuroendocrine tumor patients. Conclusion. In summary, a nomogram model was constructed in this study based on five variables (lymphatic metastasis, international normalized ratio (INR), prothrombin time (PT), tumor differentiation, and number of tumor metastases), which was shown to predict the survival probability of patients with neuroendocrine tumors. Additionally, the proposed nomogram exhibited good ability in predicting survival probability, which may be easily adopted for clinical use.

The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients

2016 ◽  
Vol 51 (10) ◽  
pp. 1172-1178 ◽  
Author(s):  
Jens F. Rehfeld ◽  
Birgitte Federspiel ◽  
Mikkel Agersnap ◽  
Ulrich Knigge ◽  
Linda Bardram
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document